Observed Signal · Nov 9, 2026 · corporate_event · Source: SEC API · Impact: 2.4/5
6-K Financial Filing Analysis for Novo Nordisk (2026-11-09)
On November 9, 2026, Novo Nordisk published a Form 6-K providing an operational update on its ongoing share repurchase programme conducted under EU Market Abuse Regulation Safe Harbour rules. The update covers market repurchases executed between November 3 and November 6, 2026, during which the company acquired 890,000 B shares for a total consideration of approximately DKK 243.65 million. This tranche forms part of the broader DKK 15 billion annual buyback programme launched on February 4, 2026, and the specific DKK 11.2 billion sub-programme running through February 1, 2027. Following these transactions, Novo Nordisk holds 56,644,876 B shares in treasury, representing 1.3% of its total share capital of 4,465,000,000 shares. In total, since February 4, 2026, the company has repurchased 42,604,179 B shares for an aggregate transaction value of DKK 11.81 billion at an average price of DKK 277.16 per share, underscoring ongoing disciplined capital returns to shareholders backed by strong cash flow from its core diabetes and obesity franchises.
This is a routine weekly execution disclosure under an existing DKK 15 billion share repurchase programme, confirming steady capital allocation progress without signaling changes to corporate strategy or operational guidance.
SIGNAL MONITORING
Receive future signals for Novo Nordisk in your briefing
Polaris7 regularly checks official registries, company newsrooms, regulatory filings, and industry sources—delivering structured Watchlist briefings when relevant changes occur.
- Primary-source verification
- Structured Watchlist briefings
- Preserves current context
Key Takeaways & Evidence Grounding
- Novo Nordisk repurchased 890,000 B shares between November 3 and November 6, 2026, bringing accumulated purchases under the current sub-programme to 27,845,000 B shares totaling DKK 8.01 billion.
- Since February 4, 2026, total buybacks under the overall DKK 15 billion annual programme reached 42,604,179 B shares at an average price of DKK 277.16, representing DKK 11.81 billion in capital returned.
- Novo Nordisk holds 56,644,876 treasury B shares, representing 1.3% of total share capital (4,465,000,000 total A and B shares).
Connected Companies & Entities
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
6-K Financial Filing Analysis for Novo Nordisk (2026-10-19)
Novo Nordisk filed a Form 6-K on October 19, 2026, detailing weekly transaction activity under its ongoing share repurchase programme conducted in accordance with EU Market Abuse Regulation safe harbour rules. Between October 12 and October 16, 2026, the company repurchased 1,225,000 Class B shares for a total consideration of DKK 316,147,881, bringing the total accumulated under the sub-programme initiated on May 6, 2026, to 24,315,000 B shares valued at DKK 7,075,024,314. Overall, under the broader 12-month DKK 15 billion buyback programme initiated on February 4, 2026, Novo Nordisk has acquired 39,074,179 B shares for a total of DKK 10,875,024,304 at an average price of DKK 278.32 per share. Following these transactions, Novo Nordisk holds 53,114,876 treasury B shares, representing approximately 1.2% of the company's total share capital.
6-K Financial Filing Analysis for Novo Nordisk (2026-11-03)
Novo Nordisk published a regular weekly transaction update under its ongoing share repurchase programme, executed pursuant to EU Market Abuse Regulation Safe Harbour rules. During the trading week ending 2 November 2026, the company repurchased 1,440,000 B shares across six trading sessions for a total transaction value of DKK 377,016,699, bringing cumulative buybacks under the sub-programme initiated on 6 May 2026 to 26,955,000 B shares (DKK 7.76 billion). Following these transactions, Novo Nordisk holds 55,754,876 B shares as treasury stock, representing approximately 1.2% of its total share capital. Across the broader 12-month DKK 15 billion buyback framework launched on 4 February 2026, the company has repurchased an aggregate of 41,714,179 B shares for DKK 11.56 billion.
6-K Financial Filing Analysis for Novo Nordisk (2026-10-26)
Novo Nordisk reported weekly transaction updates under its ongoing share repurchase programme, part of an overall 12-month buyback of up to DKK 15 billion initiated on February 4, 2026. Under the sub-programme initiated May 6, 2026 (authorizing up to DKK 11.2 billion through February 1, 2027), the company repurchased 1,200,000 B shares between October 19 and October 23, 2026, for a total weekly transaction value of approximately DKK 312.3 million at average prices ranging from DKK 257.23 to DKK 262.77. Following these transactions, Novo Nordisk holds 54,314,876 B shares in treasury, representing 1.2% of its total share capital. Across the broader 12-month program since February 4, 2026, the company has repurchased an aggregate of 40,274,179 B shares for DKK 11.19 billion at an average price of DKK 277.78 per share, continuing its disciplined capital return strategy.
WATCHLIST & BRIEFINGS
Receive future signals for Novo Nordisk & competitors in your briefing
Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.
- Regular primary-source checks
- Structured Watchlist briefings
- Preserves current context
Market Signal Monitoring
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
Monitor Novo Nordisk
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
